Ms. Walker joined Baird Capital’s Venture Capital team in 2013 and focuses on healthcare investments. Ms. Walker is a current member of the Board of Directors at Palyon Medical Corporation, NeoChord, NeuMoDx, Elucent Medical and Molecular Imaging. Prior to joining Baird Capital, she managed the strategic planning, market development, and product portfolio initiatives for multiple brands in discrete and continuous blood glucose monitoring for Abbott Ventures. Previously, Ms. Walker was with ONSET Ventures, specializing in seed and early-stage healthcare technology investments.
At Guidant Corporation, Ms. Walker held roles in operations, product design & development, engineering management, and marketing. Ms. Walker’s educational background includes a BS in Mechanical Engineering from Stanford University, an MBA from the Kellogg School of Management and an MEM (Masters of Engineering Management) from the McCormick School of Engineering at Northwestern University.
Scott is a Managing Director at Venture Investors, a leading provider of seed and early stage venture capital with over $250M in management. Scott joined the firm in 1996 and focuses on healthcare investment opportunities in medical devices, healthcare technology and technology enabled services. He created the firm’s Venture Igniter program to encourage and support academic and student led start-ups.
Scott currently represents Venture Investors on the Board of Directors for HealthMyne, Silatronix, and Elucent Medical. He serves on the Board of Advisors for the University of Wisconsin’s Chemistry Department, is a member of the Madison Development Corporation’s Debt Advisory Committee, and is a frequent guest lecturer at the UW Madison Business and Engineering schools. Scott serves as a mentor and advisor to many faculty and student lead starts-ups from the University of Wisconsin. Prior to joining Venture Investors, Scott worked for McDonald’s Corporation and Rockwell Automation. He is a graduate of the University of Wisconsin-Madison (BS–Mechanical Engineering), The University of Chicago (MBA) and is a Chartered Financial Analyst (CFA).
Professor Dan van der Weide is co-founder, Chief Technical Officer and member of the Board of Directors at Elucent Medical. He co-founded NeuWave Medical and Optametra, both of which had successful exits, and continues to be involved in early-stage ventures, both as a founder and as an advisor.
Ms. King is Founder and CEO of Elucent Medial, a company that has developed a medical device to locate breast tumors in surgery while concurrently eliminating a painful and expensive wire localization procedure from breast cancer treatment.
Prior to Elucent, Ms. King led NeuWave Medical, a Madison, WI based start-up that developed and commercialized a device to ablate cancer tumors in liver, kidney, lung and bone. Ms. King led NeuWave Medical for seven years, successfully raising $33 M in venture capital and doubling revenue each year. NeuWave had a very successfully exit, selling to JnJ Ethicon in 2016. Prior to joining the start-up world, Ms. King was a GE company officer while leading the $1.2 B Global Interventional Cardiology and Surgery business. Raised in San Francisco, CA, she is a graduate of UC Davis in Economics.